Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced <scp>HCC</scp>

Authors

Institutions

Publication Details

Journal
Liver International
Published
2026-01-09
DOI
https://doi.org/10.1111/liv.70512
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
24.20
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC

Xin Xiang, Yang Yu
1 citations
Liver International
Cancer Immunotherapy and Biomarkers
24.20
article

Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC

Xin Xiang, Yang Yu
article en
1 citations

Abstract

No abstract available for this paper.
Liver InternationalVol. 46(2)
Southwest Medical University (CN)
Openalex Percentile: Top 3%
Cancer Immunotherapy and Biomarkers
24.20
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced <scp>HCC</scp> — Xin Xiang, Yang Yu · Liver International (2026) | TGRS Research Map | TGRS